<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316351</url>
  </required_header>
  <id_info>
    <org_study_id>CROC2002</org_study_id>
    <nct_id>NCT04316351</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance</brief_title>
  <official_title>Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance：a Phase II,Muti-center, Single Arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multi-center, phase II exploratory study that evaluates&#xD;
      the efficacy and safety of Toripalimab injection (JS001) combined with Pemetrexed and&#xD;
      Anlotinib as a second-line treatment for patients with T790M positive Non-Small Cell Lung&#xD;
      Cancer (IIIb / IV ) after Osimertinib resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate （ORR）</measure>
    <time_frame>two years</time_frame>
    <description>Defined as percentage of participants achieving complete response (CR) and partial response (PR) assessed by the Independent Review Committee (IRC) according to the RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>two years</time_frame>
    <description>assessed by IRC and researchers based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>two years</time_frame>
    <description>assessed by IRC and researchers based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>two years</time_frame>
    <description>assessed by IRC and researchers based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease response (DOR)</measure>
    <time_frame>two years</time_frame>
    <description>assessed by IRC and researchers based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall incidence of adverse events (AE)</measure>
    <time_frame>two years</time_frame>
    <description>overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy</condition>
  <arm_group>
    <arm_group_label>Toripalimab + Pemetrexed + Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab + Pemetrexed + Anlotinib</intervention_name>
    <description>Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).&#xD;
If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit.</description>
    <arm_group_label>Toripalimab + Pemetrexed + Anlotinib</arm_group_label>
    <other_name>JS001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fully understand this study and voluntarily sign the informed consent form (ICF);&#xD;
&#xD;
          2. Histologically and/or cytologically confirmed Stage IIIb / IV NSCLC (according to the&#xD;
             seventh edition of AJCC); patients with T790M-positive mutations who were resistant to&#xD;
             Osimertinib treatment;&#xD;
&#xD;
          3. At least one measurable lesion (according to RECIST 1.1); Note: Lesions that have&#xD;
             previously received radiotherapy cannot be regarded as target lesions, unless the&#xD;
             lesions clearly progress after radiotherapy;&#xD;
&#xD;
          4. Agree to provide formalin-fixed tumor specimens or biopsy specimens after the subject&#xD;
             is diagnosed with metastatic cancer, at least 15 sections; if the recent biopsy is not&#xD;
             feasible, allow to receive biopsy specimens before adjuvant/neo-adjuvant chemotherapy&#xD;
             (archived specimens);&#xD;
&#xD;
          5. ECOG PS 0-2&#xD;
&#xD;
          6. Life expectancy ≥3 months.&#xD;
&#xD;
          7. The laboratory examination results within 7 days before enrollment must meet the&#xD;
             following standards:&#xD;
&#xD;
               1. Neutrophils ≥1.5 × 109 / L;&#xD;
&#xD;
               2. Platelets ≥100 × 109 / L;&#xD;
&#xD;
               3. Hemoglobin ≥90g / L (no infusion of concentrated red blood cells within 4 weeks);&#xD;
&#xD;
               4. Serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL / min;&#xD;
&#xD;
               5. Total serum bilirubin ≤ 1.5 × ULN;&#xD;
&#xD;
               6. AST and ALT ≤ 2.5 × ULN; in patients with liver metastases, ALT and AST ≤ 5 ×&#xD;
                  ULN;&#xD;
&#xD;
               7. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × ULN unless&#xD;
                  the subject is receiving anticoagulant therapy; Activated partial thrombin time&#xD;
                  (aPTT) or partial thrombin time (PTT) ≤ 1.5 × ULN unless the subject is receiving&#xD;
                  anticoagulant therapy.&#xD;
&#xD;
          8. Women of childbearing age must confirm that the serum pregnancy test is negative and&#xD;
             agree to use effective contraception during drug use and within 60 days after the last&#xD;
             dose. Women of childbearing age are defined as sexually mature women in this program:&#xD;
             1) not undergoing hysterectomy or bilateral ovariectomy, 2) natural menopause has not&#xD;
             continued for 12 months (amenorrhea after cancer treatment does not exclude&#xD;
             fertility).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Incorporate other driver gene mutations with known drug treatments, including but not&#xD;
             limited to: ALK gene rearrangement, ROS1 mutation, BRAF600E mutation, etc .;&#xD;
&#xD;
          2. Received systemic chemotherapy for advanced NSCLC within 4 weeks before enrollment;&#xD;
&#xD;
          3. Have received EGFR-TKI treatment within 2 weeks before enrollment;&#xD;
&#xD;
          4. Received radiotherapy within 4 weeks or radiopharmaceutical treatment within 8 weeks&#xD;
             before enrollment, except for local palliative radiotherapy for bone metastases;&#xD;
&#xD;
          5. Uncontrollable or symptomatic hypercalcemia (&gt; 1.5mmol / L ionized calcium or calcium&gt;&#xD;
             12 mg / dL or corrected serum calcium&gt; ULN);&#xD;
&#xD;
          6. Have undergone major surgery or have not completely recovered from the previous&#xD;
             operation within 4 weeks before enrollment ;&#xD;
&#xD;
          7. The toxicity of previous antitumor treatment has not recovered to CTCAE 0-1, except&#xD;
             for hair loss；&#xD;
&#xD;
          8. Active or untreated CNS metastases detected by CT or MRI before screening and imaging&#xD;
             evaluation: If a new asymptomatic CNS metastases is detected during the screening&#xD;
             period , it must undergo radiation therapy and / or surgery . After treatment, if met&#xD;
             all other criteria, no additional brain scan is required . Patients who have&#xD;
             previously received brain or meningeal metastasis treatment and maintained clinical&#xD;
             stability for at least 2 weeks, stopped systemic hormonal therapy (&gt; 10 mg / day of&#xD;
             prednisone or other equivalent hormones) for more than 2 weeks can be included;&#xD;
&#xD;
          9. Spinal cord compression that has not undergone radical surgery and / or radiation&#xD;
             therapy, or previously diagnosed spinal cord compression with no clinical evidence&#xD;
             showing that the disease is stable for ≥ 4 weeks before enrollment&#xD;
&#xD;
         10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated&#xD;
             drainage (once a month or more frequently);&#xD;
&#xD;
         11. have a history of idiopathic pulmonary fibrosis, organizing pneumonia (such as&#xD;
             occlusive bronchiolitis), drug-induced pneumonia, idiopathic pneumonia, or have&#xD;
             evidence of active pneumonia detected by chest CT;&#xD;
&#xD;
         12. Clinically uncontrolled active infections, including but not limited to acute&#xD;
             pneumonia;&#xD;
&#xD;
         13. Past or present with other malignancies (except for non-melanoma skin basal cell&#xD;
             carcinoma, breast / cervical carcinoma in situ, and other malignancies that have not&#xD;
             been treated in the past five years and have been effectively controlled);&#xD;
&#xD;
         14. The patients have any active autoimmune disease or a history of autoimmune disease&#xD;
             (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis,&#xD;
             pituitary inflammation, nephritis, hyperthyroidism, reduced thyroid function; Patients&#xD;
             with vitiligo or childhood asthma that have completely recovered and do not require&#xD;
             any intervention in adults can be included; asthma with bronchodilators required for&#xD;
             medical intervention cannot be included);&#xD;
&#xD;
         15. Known clinically significant liver diseases, including active viral hepatitis,&#xD;
             alcoholic hepatitis or other hepatitis, cirrhosis, fatty liver, hereditary liver&#xD;
             disease, uncontrollable major seizures, or superior vena cava syndrome;&#xD;
&#xD;
         16. Previously used anti-PD-1 antibody, anti-PD-L1 antibody or anti-CTLA-4 antibody (or&#xD;
             any other antibody acting on T cell co-stimulation or checkpoint pathway).&#xD;
&#xD;
         17. Patients with active tuberculosis (TB) are receiving antituberculosis treatment or&#xD;
             have received antituberculosis treatment within 1 year before screening;&#xD;
&#xD;
         18. After obtaining the approval of the clinical monitor, patients within 4 weeks before&#xD;
             the first medication patients receiving systemic immunosuppressive drugs (including&#xD;
             but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate,&#xD;
             thalidomide, and TNF-α ) or receiving short-term, low-dose systemic immunosuppressive&#xD;
             drugs or receiving one-time shock therapy with systemic immunosuppressive drugs (eg,&#xD;
             48 hours of glucocorticoid treatment for contrast allergic reactions) can be enrolled&#xD;
             in the study. Patients receiving mineralocorticoids (such as fludrocortisone),&#xD;
             corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose&#xD;
             corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible to&#xD;
             participate in the study;&#xD;
&#xD;
         19. Have received any anti-infective vaccine (such as influenza vaccine, chickenpox&#xD;
             vaccine, etc.) within 4 weeks before enrollment;&#xD;
&#xD;
         20. A pregnant or lactating woman or a woman who may be pregnant have a positive pregnancy&#xD;
             test before the first use of the drug; a patient with fertility who is unwilling to&#xD;
             receive contraceptives or her sexual partner is unwilling to receive contraceptives;&#xD;
&#xD;
         21. History of HIV infection&#xD;
&#xD;
         22. Patients who had obvious hemoptysis (&gt;50ml/day) within 3 months before enrollment;&#xD;
             Patients who experienced bleeding symptoms of clinical significance or with confirmed&#xD;
             bleeding tendency such as hemorrhage of digestive tract, hemorrhagic gastric ulcer,&#xD;
             baseline occult blood in stool ++ and above, or vasculitis, etc within 3 months before&#xD;
             enrollment ;&#xD;
&#xD;
         23. Any other disease or condition of clinical significance that the investigator believes&#xD;
             may affect protocol compliance, or affect the signing of an ICF, or is not suitable&#xD;
             for participation in this clinical trial;&#xD;
&#xD;
         24. A history of severe allergies, allergies or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins;&#xD;
&#xD;
         25. Patients who are allergic to known biological drugs produced by Chinese hamster ovary&#xD;
             cells, or citric acid monohydrate, sodium citrate dihydrate, mannitol, polysorbate (a&#xD;
             component of the test drug);&#xD;
&#xD;
         26. Patients who have previously received an allogeneic stem cell or parenchymal organ&#xD;
             transplant.&#xD;
&#xD;
         27. CT or MRI shows that tumor locate within a distance of less than 5 mm from the large&#xD;
             vessels, or there is a central tumor that invades the local large blood vessels; or&#xD;
             there are obvious pulmonary cavity or necrotic tumors;&#xD;
&#xD;
         28. Patients who manifested arterial/venous thrombus events, e.g. cerebrovascular accident&#xD;
             (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep&#xD;
             venous thrombosis and pulmonary embolism, etc., within 12 months before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>zhou cheng zhi, Doctor</last_name>
    <phone>(+86)13560351186</phone>
    <email>doctorzcz@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhou Chengzhi</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengzhi Zhou, Professor</last_name>
      <phone>13560351186</phone>
      <email>doctorzcz@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>Zhou Chengzhi</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

